Clinical Drug Investigation

, Volume 39, Issue 3, pp 285–299 | Cite as

HIV Integrase Inhibitor Pharmacogenetics: An Exploratory Study

  • Derek E. Murrell
  • David B. Cluck
  • Jonathan P. Moorman
  • Stacy D. Brown
  • Ke-Sheng Wang
  • Michelle M. Duffourc
  • Sam HarirforooshEmail author
Original Research Article


Background and Objectives

Integrase strand transfer inhibitors (INSTIs), dolutegravir, elvitegravir, and raltegravir, have become integral in the treatment of HIV, with close monitoring of continued efficacy and tolerability. As side effect occurrence varies among subjects receiving these drugs, we sought to perform an exploratory analysis examining the role of several single-nucleotide polymorphisms (SNPs) on drug concentration changes, selected clinical outcomes, and the occurrence of subject-reported adverse events.


Adults (aged ≥ 18 years) receiving INSTI-based regimens for treatment of HIV were recruited and genotyped with an iPLEX ADME PGx Pro v1.0 Panel. Multiple linear or logistic regression with covariates [age, sex, BMI, regimen (in the across-regimen group), regimen duration, and baseline variables (for continuous parameters)] was used to detect significant (p < 0.05) association of selected clinical data with genetic variants within the study population.


In a sample (n = 88) with a median age of 52.5 years (IQR 45.7–57.2) being predominately Caucasian (88.6%) and male (86.4%), this exploratory study discovered several associations between variables and SNPs, when using INSTIs. Abnormal dream occurrence was statistically different (p = 0.028) between regimens. Additionally, several SNPs were found to be associated with adverse event profiles primarily when all regimens were grouped together.


The associations found in this study point to a need for further assessment, within the population living with HIV, of factors contributing to unfavorable subject outcomes. These exploratory findings require confirmation in larger studies, which then may investigate pharmacogenetic mechanisms.



Portions of this article were published in dissertation form in fulfillment of the requirements for the Ph.D. Program for Derek E. Murrell. The Vanderbilt VANTAGE Core provided technical assistance for this work. VANTAGE is supported in part by CTSA Grant (5UL1 RR024975-03), the Vanderbilt Ingram Cancer Center (P30 CA68485), the Vanderbilt Vision Center (P30 EY08126), and NIH/NCRR (G20 R030956). We would like to thank Angela Hanley for her help with recruitment and sample handling; everyone involved at the ETSU Center of Excellence in HIV/AIDS care, especially Susan Dotson for initiating patient contact; and the Eastman Chemical Company and Dr. Rainey Garland for their assistance with drug analysis. Finally, we would like to thank the numerous people involved in the completion of this study and the volunteers who participated.

Author Contributions

DM: Designed research, performed research, analyzed data, and wrote manuscript; DC: Designed research, performed research, and wrote manuscript; JM: Designed research, performed research, and wrote manuscript; SB: Performed research, analyzed data, and wrote manuscript; KW: Designed research, analyzed data, and wrote manuscript; MD: Designed research and wrote manuscript; SH: Designed research, performed research, analyzed data, and wrote manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest.


This study was funded in part by a Research and Development Committee Interdisciplinary Grant and a Graduate Studies Student Research Grant from East Tennessee State University.

Ethics approval

All study procedures were conducted in accordance with the 1964 Helsinki Declaration (and its amendments). The study was approved by the East Tennessee State University/Veterans Affairs Medical Campus Institutional Review Board (IRB#: 1214.4sw).

Informed consent

Informed consent was obtained from study participants in the presence of at least one investigator and witness.


  1. 1.
    HIV Data and Statistics. World Health Organization; 2017. Accessed 18 June 2017.
  2. 2.
    Hewitt RG. Abacavir hypersensitivity reaction. Clin Infect Dis. 2002;34(8):1137–42. Scholar
  3. 3.
    Gandhi M, Greenblatt RM, Bacchetti P, Jin C, Huang Y, Anastos K, et al. A single-nucleotide polymorphism in CYP2B6 leads to > 3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women. J Infect Dis. 2012;206(9):1453–61. Scholar
  4. 4.
    Murrell DE, Harirforoosh S. Improving the renal profile of a human immunodeficiency virus drug combination through prodrug alteration. J Integr Nephrol Androl. 2016;3:2. Scholar
  5. 5.
    Rizk ML, Hang Y, Luo WL, Su J, Zhao J, Campbell H, et al. Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients. Antimicrob Agents Chemother. 2012;56(6):3101–6. Scholar
  6. 6.
    Parant F, Miailhes P, Brunel F, Gagnieu MC. Dolutegravir-related neurological adverse events: a case report of successful management with therapeutic drug monitoring. Curr Drug Saf. 2018;13(1):69–71. Scholar
  7. 7.
    Lampiris HW. Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor. Expert Rev Anti-infect Ther. 2012;10(1):13–20. Scholar
  8. 8.
    Murrell DE, Moorman JP, Harirforoosh S. Stribild: a review of component characteristics and combination drug efficacy. Eur Rev Med Pharmacol Sci. 2015;19(5):904–14.PubMedGoogle Scholar
  9. 9.
    Jiang J, Xu X, Guo W, Su J, Huang J, Liang B, et al. Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials. AIDS Res Ther. 2016;13(1):30. Scholar
  10. 10.
    Yagura H, Watanabe D, Kushida H, Tomishima K, Togami H, Hirano A, et al. Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1. BMC Infect Dis. 2017;17(1):622. Scholar
  11. 11.
    Wohl DA, Cohen C, Gallant JE, Mills A, Sax PE, Dejesus E, et al. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2014;65(3):e118–20. Scholar
  12. 12.
    Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382(9893):700–8. Scholar
  13. 13.
    Wyatt JE, Pettit WL, Harirforoosh S. Pharmacogenetics of nonsteroidal anti-inflammatory drugs. Pharmacogenomics J. 2012;12(6):462–7. Scholar
  14. 14.
    Elens L, Capron A, van Schaik RH, De Meyer M, De Pauw L, Eddour DC, et al. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines. Ther Drug Monit. 2013;35(5):608–16. Scholar
  15. 15.
    Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 2011;11(4):274–86. Scholar
  16. 16.
    Okubo M, Murayama N, Shimizu M, Shimada T, Guengerich FP, Yamazaki H. The CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes. J Toxicol Sci. 2013;38(3):349–54.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Garcia-Martin E, Martinez C, Pizarro RM, Garcia-Gamito FJ, Gullsten H, Raunio H, et al. CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity. Clin Pharmacol Ther. 2002;71(3):196–204. Scholar
  18. 18.
    Klein K, Zanger UM. Pharmacogenomics of cytochrome P450 3A4: recent progress toward the “missing heritability” problem. Front Genet. 2013;4:12. Scholar
  19. 19.
    Wang D, Sadee W. The making of a CYP3A biomarker panel for guiding drug therapy. J Pers Med. 2012;2(4):175–91. Scholar
  20. 20.
    Ritchie MD, Haas DW, Motsinger AA, Donahue JP, Erdem H, Raffanti S, et al. Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis. 2006;43(6):779–82. Scholar
  21. 21.
    Minuesa G, Arimany-Nardi C, Erkizia I, Cedeno S, Molto J, Clotet B, et al. P-glycoprotein (ABCB1) activity decreases raltegravir disposition in primary CD4+ P-gphigh cells and correlates with HIV-1 viral load. J Antimicrob Chemother. 2016;71(10):2782–92. Scholar
  22. 22.
    Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–81. Scholar
  23. 23.
    D’Avolio A, Carcieri C, Cusato J, Simiele M, Calcagno A, Allegra S, et al. Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. J Antimicrob Chemother. 2014. Scholar
  24. 24.
    Cusato J, Allegra S, De Nicolo A, Boglione L, Fatiguso G, Cariti G, et al. ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy. Biomed Pharmacother. 2015;69:63–9. Scholar
  25. 25.
    Simiele M, Ariaudo A, De Nicolo A, Favata F, Ferrante M, Carcieri C, et al. UPLC–MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma. J Pharm Biomed Anal. 2017;138:223–30. Scholar
  26. 26.
    Cipriano D, Burnham M, Hughes JV. Effectiveness of various processing steps for viral clearance of therapeutic proteins: database analyses of commonly used steps. Methods Mol Biol. 2012;899:277–92. Scholar
  27. 27.
    Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21(2):263–5. Scholar
  28. 28.
    Prins BP, Kuchenbaecker KB, Bao Y, Smart M, Zabaneh D, Fatemifar G, et al. Genome-wide analysis of health-related biomarkers in the UK Household Longitudinal Study reveals novel associations. Sci Rep. 2017;7(1):11008. Scholar
  29. 29.
    Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559–75. Scholar
  30. 30.
    Lepik KJ, Yip B, Ulloa A, Wang L, Toy J, Akagi L, et al. Adverse drug reactions to integrase strand transfer inhibitors. Aids. 2018. Scholar
  31. 31.
    Hamzic S, Kummer D, Milesi S, Mueller D, Joerger M, Aebi S, et al. Novel genetic variants in carboxylesterase 1 predict severe early-onset capecitabine-related toxicity. Clin Pharmacol Ther. 2017;102(5):796–804. Scholar
  32. 32.
    Normal Ranges for Common Laboratory Tests; 2015. Accessed 29 June 2018.
  33. 33.
    Ford SL, Gould E, Chen S, Margolis D, Spreen W, Crauwels H, et al. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. Antimicrob Agents Chemother. 2013;57(11):5472–7. Scholar
  34. 34.
    Khatri A, Trinh R, Zhao W, Podsadecki T, Menon R. Drug–drug interaction between the direct-acting antiviral regimen of ombitasvir–paritaprevir–ritonavir plus dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine. Antimicrob Agents Chemother. 2016;60(10):6244–51. Scholar
  35. 35.
    German P, Warren D, West S, Hui J, Kearney BP. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr. 2010;55(3):323–9. Scholar
  36. 36.
    Genvoya Prescribing Information. Gilead Sciences; 2017. Accessed 31 May 2017.
  37. 37.
    Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2006;43(5):509–15. Scholar
  38. 38.
    Olin JL, Spooner LM, Klibanov OM. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment. Ann Pharmacother. 2012;46(12):1671–7. Scholar
  39. 39.
    Tsuchiya K, Hayashida T, Hamada A, Oki S, Oka S, Gatanaga H. High plasma concentrations of dolutegravir in patients with ABCG2 genetic variants. Pharmacogenet Genom. 2017. Scholar
  40. 40.
    Wenning LA, Petry AS, Kost JT, Jin B, Breidinger SA, DeLepeleire I, et al. Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms. Clin Pharmacol Ther. 2009;85(6):623–7. Scholar
  41. 41.
    Barcelo C, Gaspar F, Aouri M, Panchaud A, Rotger M, Guidi M, et al. Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals. J Antimicrob Chemother. 2016;71(7):1933–42. Scholar
  42. 42.
    Tebas P, Kumar P, Hicks C, Granier C, Wynne B, Min S, et al. Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks. Aids. 2015;29(18):2459–64. Scholar
  43. 43.
    Gupta SK, Mi D, Moe SM, Dube MP, Liu Z. Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial. J Acquir Immune Defic Syndr. 2013;64(3):279–83.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Hiyoshi M, Uemura H, Arisawa K, Nakamoto M, Hishida A, Okada R, et al. Association between the catechol-O-methyltransferase (rs4680: Val158Met) polymorphism and serum alanine aminotransferase activity. Gene. 2012;496(2):97–102. Scholar
  45. 45.
    Song I, Borland J, Chen S, Peppercorn A, Wajima T, Piscitelli SC. Effect of fosamprenavir–ritonavir on the pharmacokinetics of dolutegravir in healthy subjects. Antimicrob Agents Chemother. 2014;58(11):6696–700. Scholar
  46. 46.
    Teppler H, Brown DD, Leavitt RY, Sklar P, Wan H, Xu X, et al. Long-term safety from the raltegravir clinical development program. Curr HIV Res. 2011;9(1):40–53. CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Tsuchiya K, Hayashida T, Hamada A, Kato S, Oka S, Gatanaga H. Low raltegravir concentration in cerebrospinal fluid in patients with ABCG2 genetic variants. J Acquir Immune Defic Syndr. 2014;66(5):484–6. Scholar
  48. 48.
    Tsuchiya K, Hayashida T, Hamada A, Oka S, Gatanaga H. Brief report: high peak level of plasma raltegravir concentration in patients with ABCB1 and ABCG2 genetic variants. J Acquir Immune Defic Syndr. 2016;72(1):11–4. Scholar
  49. 49.
    Molina JM, Clotet B, van Lunzen J, Lazzarin A, Cavassini M, Henry K, et al. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015;2(4):e127–36. Scholar
  50. 50.
    Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutierrez F, et al. Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807–18. Scholar
  51. 51.
    Arribas JR, Pialoux G, Gathe J, Di Perri G, Reynes J, Tebas P, et al. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. Lancet Infect Dis. 2014;14(7):581–9. Scholar
  52. 52.
    Mills A, Crofoot G, Ortiz R, Rashbaum B, Towner W, Ward D, et al. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data. HIV Clin Trials. 2014;15(2):51–6. Scholar
  53. 53.
    Fettiplace A, Stainsby C, Winston A, Givens N, Puccini S, Vannappagari V, et al. Psychiatric symptoms in patients receiving dolutegravir. J Acquir Immune Defic Syndr. 2017;74(4):423–31. Scholar
  54. 54.
    Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374(9692):796–806. Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Pharmaceutical Sciences, Gatton College of PharmacyEast Tennessee State UniversityJohnson CityUSA
  2. 2.Center of Excellence in Inflammation, Infectious Diseases, and ImmunityEast Tennessee State UniversityJohnson CityUSA
  3. 3.Department of Pharmacy Practice, Gatton College of PharmacyEast Tennessee State UniversityJohnson CityUSA
  4. 4.Department of Internal Medicine, Quillen College of MedicineEast Tennessee State UniversityJohnson CityUSA
  5. 5.Department of Biostatistics and Epidemiology, College of Public HealthEast Tennessee State UniversityJohnson CityUSA
  6. 6.Department of Biomedical Sciences, Quillen College of MedicineEast Tennessee State UniversityJohnson CityUSA

Personalised recommendations